Recent Updates
Recently added Catalysts
MGNX Negative Sentiment Score: 30/100

MACROGENICS, INC. (NASDAQ: MGNX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds MacroGenics, Inc. Investors of Upcoming Deadline

Key Takeaway: The law firm Bernstein Liebhard LLP has announced a deadline for investors in MacroGenics, Inc. (NASDAQ: MGNX) to file a lead plaintiff motion in a class action lawsuit. This lawsuit alleges that the company made misrepresentations regarding early interim safety data from the TAMARACK Phase 2 study of its prostate cancer drug, vobramitamab duocarmazine. The class period for the lawsuit is from March 7, 2024 to May 9, 2024, and investors are encouraged to discuss their legal rights by the deadline of September 24, 2024.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit was filed against MacroGenics for alleged misrepresentations.
  • The lawsuit concerns early interim safety data from a Phase 2 study of a prostate cancer drug.
  • Investors who purchased shares during a specific period may have lost money.

Full Press Release Details

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
Do you, or did you, own shares of MacroGenics, Inc. (NASDAQ: MGNX)?
Did you purchase your shares between March 7, 2024 and May 9, 2024, inclusive?
Did you lose money in your investment in MacroGenics, Inc.?
Do you want to discuss your rights?
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased the stock or sold puts of MacroGenics, Inc. (“MacroGenics”) (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, inclusive (the “Class Period”).   The lawsuit was filed in the United States District Court for the District of Maryland and alleges violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you purchased or acquired MacroGenics stock, and/or would like to discuss your legal rights and options please visit MacroGenics, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
According to the lawsuit, MacroGenics made misrepresentations related to early interim safety data results from the company’s TAMARACK Phase 2 study of a prostate cancer drug called vobramitamab duocarmazine.
If you wish to serve as lead plaintiff for the Class, you must file papers by September 24, 2024. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2024 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Tags

class action lawsuit

Frequently Asked Questions

What is the deadline to file a lead plaintiff motion?

The deadline to file is September 24, 2024.

What was the class period for the MacroGenics lawsuit?

The class period was from March 7, 2024, to May 9, 2024.

What allegations are made against MacroGenics?

The lawsuit alleges misrepresentations regarding safety data from a prostate cancer drug.

Do shareholders pay fees for legal representation?

No, all representation is on a contingency fee basis with no fees for shareholders.

How has Bernstein Liebhard LLP performed in class actions?

The firm has recovered over $3.5 billion for clients and is highly recognized.

Last updated: Aug 26, 2024